NurExone Demonstrates Extended Therapeutic Window of ExoPTEN Post Spinal-Cord Injury in Preclinical Study
06 sept. 2024 16h03 HE
|
NurExone Biologic Inc
NurExone demonstrates a longer timeframe of ExoPTEN treatment can be effectively administered post Spinal-Cord Injury
NurExone Biologic Invited to Present Groundbreaking ExoPTEN Therapy at Prestigious September Conferences
23 août 2024 16h03 HE
|
NurExone Biologic Inc
NurExone Biologic to present its innovative ExoPTEN therapy at key September conferences in Boston and New York, showcasing its leadership in regenerative
NurExone's ExoPTEN, loaded with siRNA, Demonstrates Ability to Target Injury and Inflammation Sites – New Study
09 août 2024 16h04 HE
|
NurExone Biologic Inc
NurExone announces promising new data for its ExoPTEN nanodrug, highlighting progress towards commercial-grade manufacturing
NurExone Announces Expansion of ExoPTEN Patent Coverage with Notice of Allowance for Japanese Patent Application
11 juin 2024 08h44 HE
|
NurExone Biologic Inc
NurExone Announces Expansion of ExoPTEN Patent Coverage with Notice of Allowance for Japanese Patent Application
RespireRx Pharmaceuticals Inc. Announces a Department of Defense Award to Fund a Phase 2 Clinical Study to Determine the Safety and Efficacy of CX1739, its Lead AMPAkine, to Improve Bladder Function in Patients with Spinal Cord Injury
29 mai 2024 08h15 HE
|
RespireRX Pharmaceuticals Inc.
Glen Rock, N.J., May 29, 2024 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTC Pink Markets: RSPI) (RespireRx or the Company), focused on the discovery and development of innovative and...
NurExone Biologic Inc. Announces Strategic Expansion to US Financial Markets with Approval of OTCQB Listing Application and DTC Eligibility
25 avr. 2024 08h35 HE
|
NurExone Biologic Inc
NurExone Biologic Inc. Announces Strategic Expansion to US Financial Markets with Approval of OTCQB Listing Application and DTC Eligibility
NurExone Presenting on Revolutionary Spinal Cord Injury Therapy at European Conference on Exosomes and Regenerative Medicine
19 avr. 2024 16h04 HE
|
NurExone Biologic Inc
NurExone Presenting on Revolutionary Spinal Cord Injury Therapy at top European Conference on Exosomes and Regenerative Medicine
RespireRx Pharmaceuticals Inc. Reports Publication of Preclinical Research Results Demonstrating the Ability of CX1739, its Lead Clinical AMPAkine, to Improve Bladder Function After Spinal Cord Injury
20 mars 2024 08h30 HE
|
RespireRX Pharmaceuticals Inc.
Glen Rock, N.J., March 20, 2024 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTC Pink Market: RSPI) (“RespireRx” or the “Company”), focused on the discovery and development of innovative and...
NurExone Presenting Novel Regulatory Pathways for Exosomes Therapies at Global Summit
01 mars 2024 16h04 HE
|
NurExone Biologic Inc
NurExone Presenting Novel Regulatory Pathways for Exosomes Therapies at Global Summit
Climate Change Challenge Creates Solutions for Vulnerable Populations
20 févr. 2024 15h57 HE
|
Praxis Spinal Cord Institute
Vancouver, BC, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Praxis Spinal Cord Institute NEWS RELEASEFor Immediate Release February 20, 2024 Climate Change Challenge Creates Solutions for Vulnerable...